Boston Therapeutics Expands Medical Advisory Board

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Boston Therapeutics Expands Medical Advisory Board

MANCHESTER, NH--(Marketwired - Aug 5, 2014) - Boston Therapeutics, Inc. ( OTCQB : BTHE ) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes, has expanded its Medical Advisory Board with the appointments of Meng H Tan, M.D., Philip Raskin, M.D., and Charles M. Clark, Jr., M.D. as advisors.

Dr. Tan is a professor of internal medicine (Metabolism, Endocrinology and Diabetes) at the University of Michigan. A past president of the Canadian Diabetes Association, senior medical director of the Diabetes Endocrine Platform Team and distinguished medical fellow of Eli Lilly and Company, he is a member of the American Diabetes Association and fellow of the American College of Endocrinology. Dr. Tan received his M.D. degree from Dalhousie University.

Dr. Raskin is the Clifton and Betsy Chair in Biomedical Research and professor of medicine at the University of Texas Southwestern Medical Center in Dallas. He is also director of the diabetes clinic and former director of the University Diabetes Treatment Center at Parkland Memorial Hospital in Dallas. A member of the American Diabetes Association, he is the editor of the Journal of Diabetes and Its Complications . He received his M.D. degree from the University of Pittsburgh.

Dr. Clark is professor emeritus of medicine at Indiana University Medical Center in Indianapolis. A past president of the American Diabetes Association, he has served as chairman of the National Diabetes Education Program Steering Committee and as editor of Diabetes Care . He has also served as chair of the Conference on the Worldwide Burden of Diabetes. He received his M.D. degree from Indiana University School of Medicine.

Larry K. Ellingson, chair of Boston Therapeutics' Medical Advisory Board, said, "The appointment of Doctors Tan, Raskin and Clark to the Board bring Boston Therapeutics additional distinguished diabetes experts who will provide unique expertise to help guide the Company through its future medical and scientific endeavors."

David Platt, Chief Executive Officer of Boston Therapeutics, said, "We are extremely fortunate to have attracted Doctors Tan, Raskin and Clark to our Medical Advisory Board. We look forward to their keen insights to our clinical and scientific plans."

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, ( OTCQB : BTHE ) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320 (formerly PAZ320), a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. The company also produces and sells SUGARDOWN ® , a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com .

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.

Contact: Boston Therapeutics, Inc. Anthony Squeglia Chief Financial Officer Phone: 603-935-9799 Email: anthony.squeglia@bostonti.com www.bostonti.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 70

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 25

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 69

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 147

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 91

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 118

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading

Top 5 Most Recently Viewed Articles

Uncovering Surveillance Pricing: Consumer Watchdog's New Insights

Updated Category News Views 124

Understanding Surveillance Pricing in Today's Market As we continue to navigate the digital landscape, a new and concerning practice has emerged within the retail and e-commerce sectors — surveillance pricing. This strategy allows corporations to charge different prices to consumers for the same item based on their personal data and online behavior, as highlighted by...

Continue Reading
Understanding Voting Rights and Capital at Albion Technology

Updated Category News Views 136

Total Voting Rights and Capital Overview Albion Technology & General VCT PLC In accordance with Disclosure Guidance and Transparency Rule 5.6.1, we at Albion Technology & General VCT PLC are providing key insights into our voting rights and capital structure. Issued Share Capital Details As of the recent update, the issued share capital and voting rights of the Company...

Continue Reading
Hisense Unveils Cutting-Edge Smart Home Solutions at IFA

Updated Category News Views 130

Transforming Everyday Living with Hisense Smart Technology Leading the way in home technology, Hisense recently showcased a range of innovative smart home solutions designed to enhance daily living at the IFA 2024 trade show. As a prominent name in consumer electronics, Hisense is committed to elevating the smart living experience for users worldwide. Hisense's Dedication...

Continue Reading
Jeffs’ Brands Enters Strategic Agreement for Security Tech Expansion

Updated Category News Views 296

Exploring New Horizons: Jeffs’ Brands' Non-Binding MOU The 3D, AI-Powered Technology Screens 25,000 People Per Hour—Without Stopping Them In an exciting development for Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (NASDAQ: JFBR, JFBRW), a leading data-driven e-commerce firm leveraging the Amazon Marketplace, the company has announced its wholly owned...

Continue Reading
Garmin and Global Researchers Unveil Groundbreaking Happiness Study

Updated Category News Views 175

Introduction to the Health and Happiness Study Garmin, known for its innovative technology, has embarked on an exciting journey in collaboration with researchers from prestigious institutions aimed at understanding the intricate relationship between technology, happiness, and wellbeing. This Health and Happiness Study represents a significant step forward in the quest to...

Continue Reading